Times Square Capital Management, LLC Sarepta Therapeutics, Inc. Transaction History

Times Square Capital Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 05, 2019	SELL	$72.81 - $156.91 $91.4 Million - $197 Million	-1,255,160 Closed	0 $0
Q2 2019 Aug 02, 2019	BUY	$112.21 - $151.95 $17.9 Million - $24.2 Million	159,225 Added 14.53%	1,255,160 $191 Million
Q1 2019 May 10, 2019	BUY	$106.67 - $151.68 $24.9 Million - $35.4 Million	233,345 Added 27.05%	1,095,935 $131 Million
Q4 2018 Feb 14, 2019	SELL	$97.32 - $148.76 $26 Million - $39.7 Million	-266,660 Reduced 23.61%	862,590 $94.1 Million
Q3 2018 Nov 14, 2018	BUY	$115.31 - $161.51 $47.4 Million - $66.4 Million	411,350 Added 57.3%	1,129,250 $0
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $3.57 Million - $7.65 Million	49,800 Added 7.45%	717,900 $94.9 Million
Q1 2018 May 15, 2018	BUY	$54.02 - $82.27 $9.55 Million - $14.5 Million	176,850 Added 36.0%	668,100 $49.5 Million
Q4 2017 Feb 14, 2018	BUY	$47.64 - $56.75 $800,352 - $953,400	16,800 Added 3.54%	491,250 $27.3 Million
Q3 2017 Nov 09, 2017	BUY	$35.73 - $47.15 $17 Million - $22.4 Million	474,450	474,450 $21.5 Million

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.6B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Times Square Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Times Square Capital Management, LLC with notifications on news.